Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: A systematic review

European Urology

Volumn 61, Issue 1, 2012, Pages 128-145

  Zuiverloon, Tahlita C M ^a   Nieuweboer, Annemieke J M ^a   Vékony, Hedvig ^a   Kirkels, Wim J ^a   Bangma, Chris H ^a   Zwarthoff, Ellen C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Bacillus Calmette Gu rin; BCG; Cytokine; Immune response; Immunotherapy; Interleukin; Intravesical instillation; Molecular marker; Non muscle invasive bladder cancer; Progression; Recurrence; Single nucleotide polymorphism; SNP; Survival

Indexed keywords

BCG VACCINE; CYTOKINE; DNA; EZRIN; FIBRONECTIN; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 8; KI 67 ANTIGEN; MOLECULAR MARKER; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

BLADDER CANCER; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CYSTOSCOPY; CYTOKINE PRODUCTION; DENDRITIC CELL; DNA SEQUENCE; ENZYME IMMUNOASSAY; EXCISION REPAIR; GENE EXPRESSION; GENETIC POLYMORPHISM; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGE; NATURAL KILLER CELL; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; TUMOR VOLUME; URINE LEVEL;

ADMINISTRATION, INTRAVESICAL; BCG VACCINE; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOTHERAPY; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 82255192477     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.09.026     Document Type: Review

References (91)

1. M. Babjuk, W. Oosterlinck, and R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder Eur Urol 54 2008 303 314
2. H.W. Herr, and A. Morales History of bacillus Calmette-Guérin and bladder cancer: an immunotherapy success story J Urol 179 2008 53 56 (Pubitemid 350216725)
3. A. Morales, D. Eidinger, and A.W. Bruce Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors J Urol 116 1976 180 183
4. O. Shahin, G.N. Thalmann, C. Rentsch, L. Mazzucchelli, and U.E. Studer A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guérin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival J Urol 169 2003 96 100 discussion 100 (Pubitemid 35461560)
5. R.J. Sylvester, A.P. van der Meijden, and D.L. Lamm Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
6. V. Pansadoro, P. Emiliozzi, F. de Paula, P. Scarpone, A. Pansadoro, and C.N. Sternberg Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience Urology 59 2002 227 231 (Pubitemid 34134520)
7. J.W. Davis, S.I. Sheth, M.J. Doviak, and P.F. Schellhammer Superficial bladder carcinoma treated with bacillus Calmette-Guérin: progression-free and disease specific survival with minimum 10-year followup J Urol 167 2002 494 500 discussion 501 (Pubitemid 34074513)
8. M.H. Ali, I.Y. Ismail, A. Eltobgy, and A. Gobeish Evaluation of second-look transurethral resection in restaging of patients with nonmuscle-invasive bladder cancer J Endourol 24 2010 2047 2050
9. B.W. Van Rhijn, T.H. Van der Kwast, and D.M. Kakiashvili Pathological stage review is indicated in primary pT1 bladder cancer BJU Int 106 2010 206 211
10. M. Aydin, Z. Tandogdu, F.O. Kurtulus, E. Avci, A. Fazlioglu, and M. Cek A prospective evaluation of second transurethral resection in non-muscle invasive bladder tumors J BUON 15 2010 514 517
11. G. Dalbagni, K. Vora, and M. Kaag Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer Eur Urol 56 2009 903 910
12. R.T. Divrik, A.F. ahin, Ü. Yildirim, M. Altok, and F. Zorlu Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial Eur Urol 58 2010 185 190
13. H.W. Herr Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guérin therapy J Urol 174 2005 2134 2137 (Pubitemid 41611754)
14. H.W. Herr, S.M. Donat, and G. Dalbagni Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol 177 2007 75 79 discussion 79 (Pubitemid 44879466)
15. P. Andius, and S. Holmang Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression BJU Int 93 2004 980 984 (Pubitemid 38758618)
16. P. Andius, O. Damm, and S. Holmang Prognostic factors in patients with carcinoma in situ treated with intravesical bacille Calmette-Guérin Scand J Urol Nephrol 38 2004 285 290 (Pubitemid 39277287)
17. J. Fernandez-Gomez, R. Madero, and E. Solsona Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guérin: the CUETO scoring model J Urol 182 2009 2195 2203
18. M. Takashi, K. Wakai, and T. Hattori Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ Int Urol Nephrol 33 2002 41 47 (Pubitemid 34575409)
19. A. Lopez-Beltran, R.J. Luque, and J. Alvarez-Kindelan Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1) Eur Urol 45 2004 606 612 (Pubitemid 38481688)
20. R.J. Sylvester, A.P.M. van der Meijden, W. Oosterlinck, W. Hoeltl, A.V. Bono for the EORTC Genito-Urinary Tract Cancer Group The side effects of bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial Eur Urol 44 2003 423 428 (Pubitemid 37185666)
21. S.A. Boorjian, F. Zhu, and H.W. Herr The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder BJU Int 106 2010 357 361
22. H.W. Herr Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy Urology 70 2007 65 68 (Pubitemid 47081102)
23. F. Saint, L. Salomon, and R. Quintela Do prognostic parameters of remission versus relapse after bacillus Calmette-Guérin (BCG) immunotherapy exist? Analysis of a quarter century of literature Eur Urol 43 2003 351 361 discussion 360-1 (Pubitemid 36427453)
24. L.R. Kavoussi, E.J. Brown, J.K. Ritchey, and T.L. Ratliff Fibronectin-mediated Calmette-Guérin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response J Clin Invest 85 1990 62 67 (Pubitemid 20030291)
25. T.L. Ratliff, L.R. Kavoussi, and W.J. Catalona Role of fibronectin in intravesical BCG therapy for superficial bladder cancer J Urol 139 1988 410 414
26. T.L. Ratliff, J.O. Palmer, J.A. McGarr, and E.J. Brown Intravesical bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of bacillus Calmette-Guérin Cancer Res 47 1987 1762 1766 (Pubitemid 17056672)
27. Y. Mao, and J.E. Schwarzbauer Fibronectin fibrillogenesis, a cell-mediated matrix assembly process Matrix Biol 24 2005 389 399 (Pubitemid 41765018)
28. S.A. Boorjian, R.K. Berglund, A.C. Maschino, C.J. Savage, and H.W. Herr Fibrin clot inhibitor medication and efficacy of bacillus Calmette-Guérin for bladder urothelial cancer J Urol 182 2009 1306 1312
29. S. Brandau, and A. Böhle Activation of natural killer cells by bacillus Calmette-Guérin Eur Urol 39 2001 518 524 (Pubitemid 32678965)
30. S. Brandau, J. Riemensberger, and M. Jacobsen NK cells are essential for effective BCG immunotherapy Int J Cancer 92 2001 697 702 (Pubitemid 32385713)
31. S. Brandau, H. Suttmann, and J. Riemensberger Perforin-mediated lysis of tumor cells by Mycobacterium bovis bacillus Calmette-Guérin-activated killer cells Clin Cancer Res 6 2000 3729 3738
32. M.P. Simons, M.A. O'Donnell, and T.S. Griffith Role of neutrophils in BCG immunotherapy for bladder cancer Urol Oncol 26 2008 341 345 (Pubitemid 351885380)
33. H. Suttmann, J. Riemensberger, and G. Bentien Neutrophil granulocytes are required for effective bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses Cancer Res 66 2006 8250 8257 (Pubitemid 44299194)
34. H. Takayama, K. Nishimura, and A. Tsujimura Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guérin instillation J Urol 181 2009 1894 1900
35. F. Saint, J.J. Patard, and J. Irani Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer Urology 57 2001 617 621 discussion 621-2
36. J.D. Beatty, S. Islam, M.E. North, S.C. Knight, and C.W. Ogden Urine dendritic cells: a noninvasive probe for immune activity in bladder cancer? BJU Int 94 2004 1377 1383 (Pubitemid 40052112)
37. P.A. Videira, F.M. Calais, and M. Correia Efficacy of bacille Calmette-Guérin immunotherapy predicted by expression of antigen-presenting molecules and chemokines Urology 74 2009 944 950
38. C. Ayari, H. LaRue, and H. Hovington Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy Eur Urol 55 2009 1386 1396
39. J.E. Talmadge, M. Donkor, and E. Scholar Inflammatory cell infiltration of tumors: Jekyll or Hyde Cancer Metastasis Rev 26 2007 373 400 (Pubitemid 350115102)
40. M. Iwamoto, H. Shinohara, and A. Miyamoto Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas Int J Cancer 104 2003 92 97 (Pubitemid 36184151)
41. L. Bingle, N.J. Brown, and C.E. Lewis The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies J Pathol 196 2002 254 265 (Pubitemid 34189413)
42. J.W. Pollard Tumour-educated macrophages promote tumour progression and metastasis Nat Rev Cancer 4 2004 71 78 (Pubitemid 38082155)
43. S.F. Schoppmann, P. Birner, and J. Stockl Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis Am J Pathol 161 2002 947 956 (Pubitemid 34988382)
44. F. Saint, J.J. Patard, and P. Maille Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guérin treatment for superficial bladder cancer J Urol 167 2002 364 367 (Pubitemid 34024586)
45. E. Watanabe, H. Matsuyama, and K. Matsuda Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder Cancer Immunol Immunother 52 2003 481 486 (Pubitemid 36963209)
46. T.M. De Reijke, E.C. De Boer, K.H. Kurth, and D.H. Schamhart Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: processing, stability and prognostic value J Urol 155 1996 477 482 (Pubitemid 26023528)
47. F. Saint, N. Kurth, and P. Maille Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guérin response of superficial bladder cancer during induction course and maintenance therapy Int J Cancer 107 2003 434 440 (Pubitemid 37266464)
48. R. Kaempfer, L. Gerez, and H. Farbstein Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression J Clin Oncol 14 1996 1778 1786 (Pubitemid 26185455)
49. G.N. Thalmann, B. Dewald, M. Baggiolini, and U.E. Studer Interleukin-8 expression in the urine after bacillus Calmette-Guérin therapy: a potential prognostic factor of tumor recurrence and progression J Urol 158 1997 1340 1344 (Pubitemid 27391191)
50. A. Kumar, D. Dubey, P. Bansal, A. Mandhani, and S. Naik Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guérin (modified Danish 1331 strain) for superficial bladder cancer J Urol 168 2002 2232 2235
51. L. Sagnak, H. Ersoy, and U. Ozok Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus Calmette-Guérin treatment in non-muscle-invasive bladder tumors Clin Genitourin Cancer 7 2009 E16 E23
52. R. Rabinowitz, D.S. Smith, D.D. Tiemann, and M.A. Hudson Urinary interleukin-8/creatinine level as a predictor of response to intravesical bacillus Calmette-Guérin therapy in bladder tumor patients J Urol 158 1997 1728 1731 discussion 1731-2
53. G.N. Thalmann, A. Sermier, C. Rentsch, K. Mohrle, M.G. Cecchini, and U.E. Studer Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guérin J Urol 164 2000 2129 2133
54. E.C. De Boer, W.H. De Jong, and A.P. Van der Meijden Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin Cancer Immunol Immunother 33 1991 411 416
55. R.J. Armitage Tumor necrosis factor receptor superfamily members and their ligands Curr Opin Immunol 6 1994 407 413 (Pubitemid 24188489)
56. A.T. Ludwig, J.M. Moore, and Y. Luo Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for bacillus Calmette- Guérin-induced antitumor activity Cancer Res 64 2004 3386 3390 (Pubitemid 38657909)
57. T.J. Kemp, A.T. Ludwig, and J.K. Earel Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guérin (BCG) results in the release of functional soluble TRAIL/Apo-2L Blood 106 2005 3474 3482 (Pubitemid 41609183)
58. E.C. De Boer, S.J. Rooijakkers, D.H. Schamhart, and K.H. Kurth Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guérin determine the succeeding Th1 response J Urol 170 2003 2004 2008 (Pubitemid 37254997)
59. K. Esuvaranathan, E. Chiong, and T.P. Thamboo Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha Cancer 109 2007 1097 1105 (Pubitemid 46435388)
60. T. Lebret, V. Becette, and M. Barbagelatta Correlation between p53 over expression and response to bacillus Calmette-Guérin therapy in a high risk select population of patients with T1G3 bladder cancer J Urol 159 1998 788 791 (Pubitemid 28106526)
61. M. Peyromaure, S. Weibing, and P. Sebe Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette- Guérin therapy Urology 59 2002 409 413 (Pubitemid 34189744)
62. A.R. Zlotta, J.C. Noel, and I. Fayt Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guérin intravesical therapy J Urol 161 1999 792 798 (Pubitemid 29422368)
63. F. Saint, M.-A. Le Frere Belda, and R. Quintela Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with bacillus Calmette-Guérin (BCG) Eur Urol 45 2004 475 482 (Pubitemid 38376210)
64. J. Palou, F. Algaba, I. Vera, O. Rodriguez, H. Villavicencio, and M. Sanchez-Carbayo Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin Eur Urol 56 2009 829 836
65. T. Lebret, V. Becette, and J.-M. Hervé Prognostic value of MIB-1 antibody labeling index to predict response to bacillus Calmette-Guerin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer Eur Urol 37 2000 654 659 (Pubitemid 30255780)
66. L. Cormio, I. Tolve, and P. Annese Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer Anticancer Res 29 2009 4201 4204
67. X. Wu, H. Zhao, and Q. Wei XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity Carcinogenesis 24 2003 505 509 (Pubitemid 36432647)
68. C.H. Bosken, Q. Wei, C.I. Amos, and M.R. Spitz An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer J Natl Cancer Inst 94 2002 1091 1099 (Pubitemid 34830729)
69. J.W. Catto, G. Xinarianos, J.L. Burton, M. Meuth, and F.C. Hamdy Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability Int J Cancer 105 2003 484 490 (Pubitemid 36578551)
70. J. Gu, H. Zhao, and C.P. Dinney Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer Clin Cancer Res 11 2005 1408 1415 (Pubitemid 40315220)
71. R.D. Mittal, R. Singh, and P.K. Manchanda XRCC1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy Cancer Biol Ther 7 2008 645 650
72. R. Gangawar, D. Ahirwar, A. Mandhani, and R.D. Mittal Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India Med Oncol 27 2010 159 166
73. R. Gangwar, A. Mandhani, and R.D. Mittal XPC gene variants: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy J Cancer Res Clin Oncol 136 2010 779 786
74. D. Leibovici, H.B. Grossman, and C.P. Dinney Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival J Clin Oncol 23 2005 5746 5756
75. D. Ahirwar, P. Kesarwani, P.K. Manchanda, A. Mandhani, and R.D. Mittal Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer Cancer Genet Cytogenet 184 2008 1 8 (Pubitemid 351814965)
76. D.K. Ahirwar, A. Mandhani, A. Dharaskar, P. Kesarwani, and R.D. Mittal Association of tumour necrosis factor-alpha gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guérin immunotherapy BJU Int 104 2009 867 873
77. T. Higuchi, N. Seki, and S. Kamizono Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese Tissue Antigens 51 1998 605 612 (Pubitemid 28306464)
78. D.K. Ahirwar, A. Mandhani, and R.D. Mittal IL-8 -251 T > A polymorphism is associated with bladder cancer susceptibility and outcome after BCG immunotherapy in a northern Indian cohort Arch Med Res 41 2010 97 103
79. B. Basturk, I. Yavascaoglu, B. Oral, G. Goral, and B. Oktay Cytokine gene polymorphisms can alter the effect of bacillus Calmette-Guérin (BCG) immunotherapy Cytokine 35 2006 1 5 (Pubitemid 44485528)
80. D.K. Ahirwar, A. Agrahari, A. Mandhani, and R.D. Mittal Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy Biomarkers 14 2009 213 218
81. M. Decobert, H. Larue, and A. Bergeron Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guérin immunotherapy for superficial bladder cancer J Urol 175 2006 1506 1511
82. Y.J. Kim, Y.S. Ha, and S.K. Kim Gene signatures for the prediction of response to bacillus Calmette-Guérin immunotherapy in primary pT1 bladder cancers Clin Cancer Res 16 2010 2131 2137
83. M.B. Atkins, M.T. Lotze, and J.P. Dutcher High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 17 1999 2105 2116 (Pubitemid 29318842)
84. G. Fyfe, R.I. Fisher, S.A. Rosenberg, M. Sznol, D.R. Parkinson, and A.C. Louie Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy J Clin Oncol 13 1995 688 696
85. W. Liu, M.A. O'Donnell, X. Chen, R. Han, and Y. Luo Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro Cancer Immunol Immunother 58 2009 1647 1655
86. Y. Luo, H. Yamada, and X. Chen Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity Clin Exp Immunol 137 2004 24 34 (Pubitemid 38869774)
87. H. Yamada, S. Matsumoto, T. Matsumoto, T. Yamada, and U. Yamashita Murine IL-2 secreting recombinant bacillus Calmette-Guérin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2 J Urol 164 2000 526 531 (Pubitemid 30481978)
88. D.A. Zaharoff, B.S. Hoffman, and H.B. Hooper Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12 Cancer Res 69 2009 6192 6199
89. X. Wang, E.K. Lam, J. Zhang, H. Jin, and J.J. Sung MicroRNA-122a functions as a novel tumor suppressor downstream of adenomatous polyposis coli in gastrointestinal cancers Biochem Biophys Res Commun 387 2009 376 380
90. E.A. Mathe, G.H. Nguyen, and E.D. Bowman MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival Clin Cancer Res 15 2009 6192 6200
91. Y. Takei, M. Takigahira, K. Mihara, Y. Tarumi, and K. Yanagihara The metastasis-associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer Cancer Res 71 2011 1442 1453